Abstract Purpose: Identification of molecular characteristics of spontaneously regressing stage IVS and progressing stage IV neuroblastoma to improve discrimination of patients with metastatic disease following favorable and unfavorable clinical courses. Experimental Design: Serial analysis of gene expression profiles were generated from five stage IVS and three stage IV neuroblastoma. Differential expression of candidate genes was evaluated by real-time quantitative reverse transcription-PCR in 76 pretreatment tumor samples (stage IVS n = 27 and stage IV n = 49). Gene expression-based outcome prediction was determined by Prediction Analysis for Microarrays using 38 tumors as a training set and 38 tumors as a test set.
Neuroblastoma is a malignant embryonal tumor of the sympathetic nervous system accounting for 7% to 8% of childhood cancers. The biological and clinical behavior of the tumor is remarkably variable ranging from spontaneous regression to fatal tumor progression. These contrasting courses of disease may even occur in patients with disseminated neuroblastoma: Whereas most metastatic tumors of children at stage IV are characterized by aggressive growth and many patients succumb to their disease despite intensive treatment, those defined as stage IVS (age V12 months and dissemination restricted to liver, bone marrow, and/or skin) regularly show spontaneous regression resulting in an excellent patient's outcome (1, 2) . Although survival rates of stage IV and IVS patients differ markedly, the precise delineation of a regressive phenotype remains challenging, and markers, such as age V12 months and metastatic pattern, are still a matter of debate (3, 4) . However, because treatment strategies of these patients may vary from a ''watch and wait'' approach to myeloablative megatherapy with autologous stem-cell rescue, precise risk group assignment is critical for therapeutic decisions.
The molecular mechanisms underlying the process of spontaneous regression are still unknown. Whereas some authors postulated that natural immunologic tumor defense mechanisms could account for this phenomenon (5, 6) , others suggested that spontaneous involution of the tumor might be a result of developmentally regulated programmed cell death of neuroblasts (1, 7 -10) . Current models of neuroblastoma tumorigenesis propose that there are at least two distinct Imaging, Diagnosis, Prognosis subtypes of neuroblastoma differing in their tumor cell biology (9) , one with the ability to regress or differentiate spontaneously and the other showing an aggressive phenotype. These two subtypes have been shown to differ from one another by several cytogenetic aberrations, such as MYCN amplification and deletions of the chromosomal regions 1p, 3p, and 11q (del1p, del3p, and del11q), all of which are associated with poor outcome (1, 2) , and more recently by distinctive gene expression signatures with strong prognostic effect (11, 12) . However, tumors of stage IVS disease were either absent or represented in minor numbers in the latter studies, and efforts of other studies to identify characteristic gene expression patterns of stage IVS tumors in comparison with stage IV neuroblastoma failed thus far (13, 14) .
In this study, gene expression patterns of stage IV and IVS tumors were investigated using serial analysis of gene expression (SAGE) and quantitative reverse transcription-PCR (QPCR) to uncover transcripts related to spontaneous regression and progression of disseminated neuroblastoma. Differentially expressed transcripts were associated to Gene Ontology (GO) annotations to identify potential biological processes occurring within the transcriptome of spontaneously regressing metastatic neuroblastoma. Finally, a supervised class prediction analysis was done to evaluate the prognostic effect of the identified candidate genes.
Materials and Methods
Characteristics of patients and tumor samples. A total of 76 pretreatment tumor samples from patients with disseminated neuroblastoma were obtained from the German tumor tissue bank (stage IV n = 49 and stage IVS n = 27), 8 of which were used for gene expression profiling by SAGE (see Table 1 ). Tumor samples were collected from patients registered in the German multicenter neuroblastoma study between 1992 and 2003 and treated according to the German NB90-NB97 trial protocols. Informed consent was obtained before analyses of tumor samples. Median age at diagnosis was 1,029 and 118 days for patients of stage IV and IVS disease, respectively, and median follow-up of patients was 3.3 years.
Sample preparation and RNA extraction. Snap-frozen tissue (20-50 mg) was cryosliced into sections and homogenized by the FastPrep FP120 cell disrupter (Qbiogene, Inc., Carlsbad, CA). Tumor content of each sample was assessed by a pathologist (K.E.) and only samples with z60% tumor cells were included. Total RNA was extracted from homogenized samples using the TRIzol reagent (Invitrogen, Karlsruhe, Germany) according to the supplier's instructions. Polyadenylate-RNA was purified using the MessageMaker messenger isolation system (Invitrogen). Integrity of total RNA samples was examined by RNA Nano Chip assays on the 2100 Bioanalyzer (Agilent Technologies, Waldbronn, Germany).
Serial analysis of gene expression. SAGE libraries were constructed from 100 to 200 ng polyadenylate-RNA or 20 Ag total RNA using the I-SAGE kit (Invitrogen) following the manufacturer's protocol. Concatemers were cloned into a plasmid vector, and clones containing inserts were automatically sequenced (MWG-Biotech, Ebersberg, Germany). Extraction of SAGE tags from sequence files and exclusion of duplicate ditags and linker tags was done using the SAGE2000 software version 4.12 (http://www.sagenet.org/sage_protocol.htm). Genes corresponding to the tags were identified by comparison with the human UniGene reference database, Build 166 (http:// www.ncbi.nlm.nih.gov/SAGE).
Quantitative reverse transcription-PCR. QPCR was done using the SYBR Green I reagent on the ABI PRISM 7700 Sequence Detection System (Applied Biosystems, Weiterstadt, Germany) as described elsewhere (15) . In brief, 5 Ag total RNA was converted into first-strand cDNA in a volume of 52.5 AL. PCR amplification was done using standard conditions in a volume of 30 AL containing 0.4 AL of 1:10 diluted firststrand cDNA, 26.8 AL of 1Â SYBR Green PCR Master Mix (Applied Biosystems), and 1.4 AL of 2.5 Amol/L forward and reverse primer each (Eurogentec, Seraing, Belgium). Primer sequences are available from the authors on request. Serial cDNA dilutions of the neuroblastoma cell line IMR-32 were used for standard curve calculation. Target gene expression levels were normalized to the geometric mean of transcript levels of the control genes SDHA and HPRT1, which have been shown to be consistently expressed in stage IV and IVS neuroblastoma (15) , and calibrated to the minimal expression value within the total set of tumors.
Data analysis and statistics. SAGE profiles of stage IV and IVS neuroblastoma were compared using t test statistics, ANOVA, and Fisher's exact test with Bonferroni correction. Calculations were carried out in R (version 2.1.0, The R Foundation for Statistical Computing; http://www.r-project.org). To identify GO categories (http://www. geneontology.org) overrepresented in the tumor subtypes, the UniGene IDs were mapped to the Locus Link/Entrez entries. Associated GO categories were obtained from the Bioconductor (16) library humanLLmappings (version 1.10.0). Only GO categories in the ''biological process'' section of GO were used. Overrepresentation of GO categories was tested by using the hypergeometric test implemented in the Bioconductor package GOstats (version 1.4.0). Distributions of normalized gene expression levels determined by QPCR in stage IV and IVS tumors were compared using the Mann-Whitney U test. For supervised class prediction analysis, the nearest shrunken centroids method [Prediction Analysis for Microarrays (PAM)] was applied (17) after expression data had been transformed by calculating the log ratio of expression values to the median expression value of each gene. The implementation in the Bioconductor package pamr (version 1.25) was used. To consider all the information from the QPCR data, the PAM 10-fold cross-validation of the training set was done with a fixed threshold of zero for no shrinkage, thereby estimating the classification accuracy of the gene signature in the training set. The threshold of zero was also used for class prediction of patients in the test set. Unsupervised cluster analysis was done using the Genesis Microarray Software Suite version 1.4.0 (http://genome.tugraz.at/Software/GenesisCenter.html). KaplanMeier estimates for event-free survival (EFS) and overall survival (OS) were calculated and compared by log-rank test. Recurrence, progression, and death of disease were considered as events. Cox's proportional hazards regression model built on EFS was used for multivariate analysis.
Results
Identification of genes differentially expressed in stage IV and IVS neuroblastoma. Gene expression profiles were generated from five samples of spontaneously regressing stage IVS disease and from three samples of fatal stage IV disease using SAGE (18) Genes corresponding to tags identified by the t test were associated to GO annotations to examine whether these transcripts can be categorized into functional classes that may provide information about the molecular basis of the distinct phenotypes. Fifty-two and 27 GO categories were overrepresented in stage IVS and IV tumors, respectively (Supplementary Table S2 ). Nine of the 52 GO categories of stage IVS tumors were related to neuronal differentiation or neuronal functions (e.g., ''positive regulation of neuronal differentiation,'' ''dendrite morphogenesis,'' ''neuron migration,'' ''neurotransmitter receptor biosynthesis,'' and ''synaptic vesicle transport''; Supplementary Table S2A ). In contrast, only two such categories were found among the GO classes of stage IV neuroblastoma (''vesicle organization'' and ''biogenesis and regulation of neurotransmitter secretion''; Supplementary Table S2B), which suggests that these tumors differ from stage IVS by gene expression patterns, reflecting distinct levels of neuronal differentiation. A less pronounced difference was observed regarding GO categories related to programmed cell death or growth control, with three of them being overrepresented in stage IVS tumors (''induction of apoptosis by intracellular signals,'' ''cell cycle arrest,'' and ''positive regulation of tumor necrosis factor-a biosynthesis,'' Supplementary Table S2A ). The GO class ''apoptosis'' was overrepresented in stage IV tumors; however, subcategories of this class comprise genes with Although SAGE results strongly suggested that neuroblastoma of stage IV and IVS disease harbor distinct gene expression patterns, the small sample numbers of this analysis might have generated an overestimation of differentially expressed transcripts. We therefore evaluated 41 genes with differential expression according to SAGE that are related to functional categories of neuronal differentiation and/or apoptosis or growth control using QPCR in a cohort of 38 neuroblastoma (stage IV n = 19 and stage IVS n = 19; Supplementary Table S3) . In this set, 18 (44%) genes showed significantly distinct transcript abundances between the two subtypes (P < 0.05). Expression levels of these 18 genes were then evaluated in an independent series of 38 tumors (stage IV n = 30 and stage IVS n = 8). Differential expression was confirmed for 16 of 18 genes in this second set (P < 0.05), and a tendency was observed for the two remaining genes CADPS and PRAME (P = 0.10 and 0.14, respectively). In the combined set of 76 samples, expression levels of all 18 genes were significantly different in stage IV and IVS tumors (P V 0.001 for each transcript; Fig. 1 ). Functional characteristics of these 18 genes are summarized in Table 2 . Expression levels of 17 genes were increased in stage IVS tumors, whereas one gene (PRAME) was down-regulated in this subset as reported previously (19) . Taken together, SAGE and QPCR analyses showed different gene expression patterns in stage IVS and IV neuroblastoma that indicate distinct levels of neuronal differentiation of the tumor cells.
Definition of neuroblastoma subtypes according to gene expression signatures. Given the fact that each single gene delineated in Fig. 1 was differentially expressed with strong statistical significance between stage IVS and IV neuroblastoma that usually correspond to regressing and progressing phenotypes, respectively, we asked whether the combined analysis of these transcripts might be able to accurately predict the biological behavior of the tumors and consequently the clinical courses of the patients. A supervised class prediction analysis was therefore done using the PAM algorithm (17) to test the prognostic value of these 18 genes. Classification accuracy was evaluated in the first set of 38 patients by cross-validation. Whereas PAM voting for most children was analogous to staging of disease, three patients with stage IV and two patients with stage IVS tumors were classified into the opposite category ( Fig. 2A) . PAM prediction was then used to classify tumors of the second series of patients (n = 38) based on expression levels of the selected 18 genes. Again, three stage IV and two stage IVS tumors were categorized into the opposite subgroup (Fig. 2B) . Hierarchical clustering of the patients using these 18 genes visualized comparable gene expression patterns of tumors showing a similar clinical behavior (Fig. 2C) . Kaplan-Meier estimates for EFS and OS of patients with a favorable (n = 29) and an unfavorable PAM voting (n = 47) differed with a higher level of significance (3-year EFS 96 F 6% versus 40 F 8%; P < 0.0001; 3-year OS 100% versus 72 F 7%; P = 0.0003; Fig. 3 ) than those of subgroups defined by stage (3-year EFS stage IVS 88 F 6% versus stage IV 46 F 8%; P = 0.0027; 3-year OS 96 F 4% versus 76 F 7%, respectively; P = 0.0044; Fig. 3A and B) . Outcome prediction by PAM was then evaluated in clinical subgroups defined by age at diagnosis and stage of disease. Infants <1 year old with an unfavorable signature (n = 6) displayed a significantly poorer outcome than those with a favorable signature (n = 25; 3-year EFS 42 F 22% versus 96 F 4%; P = 0.0008; 3-year OS 60 F 22% versus 100%; P = 0.001; Fig. 3C and D) . Patients with stage IV disease and a favorable gene signature (n = 6) had a significantly better EFS and tended to have a better OS than stage IV patients with an unfavorable signature (n = 43; 3-year EFS 100% versus 40 F 8%; P = 0.04; Fig. 3E ; 3-year OS 100% versus 73 F 7%; P = 0.1). Examination of cytogenetic aberrations of these six favorable tumors revealed that four of five patients harbored a del11q, whereas only one patient had a del1p and none of them a MYCN amplification. Three children of this subgroup were f1 year old at diagnosis (321, 359, and 371 days), but the remaining three patients were substantially older (619, 1,468, and 2,003 days). Similarly, infants with stage IVS disease and favorable PAM voting (n = 23) showed a superior EFS (96 F 4% at 3 years) compared with those with an unfavorable gene signature (n = 4; 3-year EFS 38 F 29%; P = 0.002; Fig. 3F ). The latter subgroup comprised two stage IVS patients that experienced progression into stage IV neuroblastoma, one of them with fatal outcome. One of these two patients (NB87) lacked any of the prognostic cytogenetic aberrations MYCN amplification, del1p, del3p, and del11q, whereas the other one had a del11q (NB91; Table 1 ). Of the remaining two patients, one (NB72) harbored a MYCN amplification and a del1p and is currently in complete remission after intensive treatment according to the German highrisk protocol, whereas the other patient (NB80) lacked cytogenetic aberrations and is currently in complete remission without cytotoxic treatment. Within the group of stage IVS patients with a favorable signature, one child had relapsed from disease but reached complete remission without chemotherapy thereafter (3-year OS of this group is 100%).
Finally, the prognostic variables gene signature, stage, age, and MYCN status were evaluated in a multivariate Cox regression model built on EFS for the whole set of 76 patients. Outcome prediction by the gene signature turned out to be a superior, independent prognostic marker in this series of patients (P < 0.001; hazard ratio, 21.7; 95% confidence interval, 3-160).
Discussion
Disseminated neuroblastoma exhibits a remarkable heterogeneity in its clinical and biological behavior. The contrasting phenotypes have been suggested to be due to distinct genetic programs of the tumor cells, which are supposed to be mirrored by characteristic differences on the transcriptome level (1, 7 -10) . Thus, identification of genes differentially expressed in stage IV and IVS tumors may contribute to the elucidation of the molecular mechanisms of spontaneous regression and provide novel prognostic markers that are able to accurately predict outcome of patients suffering from metastatic neuroblastoma.
In the present study, gene expression profiles of untreated neuroblastoma of stage IV and IVS disease that followed characteristic clinical courses were generated by SAGE. MYCNamplified tumors were excluded from the SAGE analysis, because MYCN amplification is observed in only a minor fraction (f30-35%; refs. 1, 9) of unfavorable neuroblastoma and results in distinctive effects on the tumor's transcriptome on its own (20, 21) , which may mask general mRNA alterations of aggressive neuroblastoma. Comparison of the SAGE profiles of stage IV and IVS tumors using various statistical tests revealed f500 differentially expressed genes. Because tumor numbers analyzed by SAGE were small and thus might have resulted in an overestimation of transcriptomic differences, 41 genes that were supposed to be differentially expressed were selected and expression levels were determined by QPCR in a series of 76 tumors of stage IV and IVS disease. Eighteen genes showed significantly diverging transcript abundances, suggesting that f50% of the f500 transcripts identified by various statistical tests are differentially expressed in these two subtypes. This finding is in contrast to results from previous microarray analyses (13, 14) that failed to reliably discover discriminating gene expression patterns of stage IVS and IV neuroblastoma, which may in part result from intrinsic methodologic differences of SAGE and microarrays (22) . However, it seems more likely that the discrepant findings are mainly due to the fact that previous studies either analyzed small sample numbers of stage IVS and IV tumors (n = 9 each; ref. 14) or used a microarray that covers only a minor fraction (4,608 cDNAs) of the human transcriptome (13) , whereas in the present study a combined approach of genome-wide expression profiling followed by an independent evaluation of single candidate transcripts in a large set of tumors was applied.
Association of transcripts identified by t test statistics to GO annotations revealed a predominance of genes related to neuronal differentiation and neuronal functions in stage IVS compared with stage IV tumors, and differential expression levels of candidate genes were confirmed by QPCR analysis. Thirteen of the 17 transcripts found to be up-regulated in stage IVS neuroblastoma by QPCR have been shown to contribute to specific processes of neuronal differentiation, to be expressed at specific stages of neuronal development, to represent markers of mature neural tissues, or to be involved in synaptic functions or transmitter release (Table 2 ). These findings may either indicate that processes of neuronal differentiation are ongoing in cells of stage IVS tumors leading to a more differentiated molecular phenotype compared with cells of stage IV tumors or that dedifferentiation occurs in neoplastic cells of the latter subtype going along with their malignant transformation. Alternatively, these two subtypes may originate from precursor cells of distinct developmental stages. Similarly, a less differentiated molecular phenotype of stage IV neuroblastoma has been observed in comparison with favorable tumors of stage I disease recently (10, 23) . However, this result might have been expected, because localized neuroblastoma of stage I or II often present a more differentiated histologic phenotype (24, 25) , and development into mature ganglioneuroma has been described to be one of the potential clinical courses in these stages of disease (26) . In contrast, the majority of both tumor cells of stage IVS and IV disease exhibit a histologically poorly differentiated stage of development (24, 25) , which applied for the set of neuroblastoma of the present study as well (Table 1) . Moreover, neuroblastoma of stage IVS disease rarely differentiate into benign ganglioneuroma but regress completely in the majority of cases (27, 28) . High expression levels of genes that are induced by the differentiating agent retinoic acid in stage IVS tumors (SYN3, MAP7, CNR1, and MEIS1; Table 2 ) may further support the notion that molecular development has been proceeded in cells of this subtype compared with those of unfavorable metastatic neuroblastoma. In addition, 12 of the genes up-regulated in stage IVS tumors have been suggested to be involved in cell growth control or to represent tumor suppressors, and 5 of these are located at chromosomal regions 3p and 11q that are frequently deleted in unfavorable neuroblastoma (PCBP4, RBM5, ROBO1, IGSF4, and scotin; Table 2 ). This observation may indicate that several mechanisms of growth control are disrupted in stage IV tumors and may add evidence to the hypothesis that spontaneous regression in neuroblastoma is due to a delayed activation of developmentally regulated programmed cell death (1, 9, 10) . It remains to be determined, however, whether down-regulation of the genes described here is causally involved in the malignant phenotype of aggressive neuroblastoma.
The classification accuracy of clinical outcome by this gene signature was examined using the PAM algorithm in a training and test set of 38 tumors each. Analysis of EFS and OS of patients with a favorable and an unfavorable PAM prediction showed that the gene signature reliably distinguished patients with beneficial and adverse outcome (Fig. 3) . As expected, classifications by PAM and by stage (stage IV versus IVS) were highly concordant but with some remarkable exceptions. Four stage IVS tumors were classified into the unfavorable subset (Figs. 2 and 3F) , two of which were characterized by progression into stage IV disease and another by a MYCN amplification. A second stage IVS tumor with a MYCN copy number of five revealed a favorable gene expression pattern. However, the prognostic influence of a few additional MYCN copies has been reported to be questionable (29, 30) ; indeed, Fig. 2 . Cross-validation probability plot of the first set of tumors (stage IV n = 19 and stage IVS n = 19; A) and prediction probability plot of the second set of tumors (stage IV n = 30 and stage IVS n = 8; B) using PAM. P < 0.5 was counted as voting for the opposite tumor class. As a fixed threshold of zero for the PAM algorithm was set, the cross-validation results can be compared with a supervised tumor class prediction. Blue dots, stage IV patients; orange dots, stage IVS patients. Top, patients'outcome (red, event; green, no event) and PAM voting (red, unfavorable; green, favorable). C, hierarchical cluster analysis of the total set of tumors according to the 18 signature genes (variables: Manhattan distance and average linkage). Red, high expression; blue, low expression. Top, patients' stage (red, stage IV; green, stage IVS), outcome (red, event; green, no event), and PAM voting (red, unfavorable; green, favorable).
this patient reached complete remission and is free of events since 3.5 years without any cytotoxic treatment. On the other hand, six children with stage IV neuroblastoma were categorized into the favorable subgroup. Although three of them were substantially older than 1 year at diagnosis and most tumors harbored cytogenetic aberrations of chromosome 11q, this subgroup was characterized by exceptionally benign clinical courses (Fig. 3E) . The strong association of favorable outcome and gene expression patterns resembling that of regressing stage IVS tumors indicates that spontaneous involution may also occur in some stage IV tumors and probably even in patients >2 years old. Although this hypothesis has to be verified carefully in prospective studies, confirmation of this finding could result in a substantial reduction of treatment intensity for these patients. One has to consider, however, that all stage IV patients classified into the favorable subgroup by PAM voting had received cytotoxic treatment, which might have influenced the outcome of these children. Finally, the prognostic value of the gene signature was evaluated in a multivariate analysis, including age, stage, and MYCN status. In this set of tumors, the PAM classifier turned out to be a superior, independent predictor of patient's outcome, thereby supporting findings of recent reports, suggesting that gene expression signatures may be highly accurate prognostic markers for neuroblastoma patients (11, 12) .
In conclusion, this is the first study that clearly shows that stage IVS and IV neuroblastoma differ by specific gene expression patterns, and classification of differentially expressed transcripts indicate distinct levels of neuronal differentiation of these two subtypes. In addition, we provide strong evidence that gene expression signatures are suitable to distinguish spontaneously regressing and progressing tumors at the time of diagnosis and thus may contribute to an improved risk estimation of patients with disseminated neuroblastoma.
